Wednesday, April 16, 2014

Author Archive

BVTI, ABPI, TLON, DCTH, ACTC, XOMA, OREX, potential big winners for 2011

BVTI, ABPI, TLON, DCTH, ACTC, XOMA, OREX, potential big winners for 2011

The following companies might be the next big movers and winners of the 2011 year. With significant milestones achieved and unique products, they are leaders in their respective fields and are ready to deliver shareholder value in the coming months.

Accentia (PINK:ABPI) is advancing potential blockbuster drug candidates

Accentia (PINK:ABPI) is advancing potential blockbuster drug candidates

Accentia is advancing a portfolio of potential blockbuster drug candidates which target multi-billion dollar market opportunities. These late-stage products include: BiovaxID®, a novel anti-idiotype cancer vaccine for the treatment of B-cell malignancies including indolent follicular non-Hodgkin’s lymphoma; Revimmune™, a novel ultra-high-dose formulation of a previously approved chemotherapeutic agent expected to show utility in the treatment of up to 80 autoimmune diseases, with an initial focus on multiple sclerosis; and SinuNase™, a novel formulation of a previously approved anti-fungal for the topical, intranasal treatment of chronic sinusitis.

Biovest International (OTC:BVTI),The Next potential winner in Cancer Immunotherapy Vaccine after Dendreon (NASDAQ:DNDN)

Biovest International (OTC:BVTI),The Next potential winner in Cancer Immunotherapy Vaccine after Dendreon (NASDAQ:DNDN)

Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies. In collaboration with the National Cancer Institute, Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed, including a Phase III study, demonstrating evidence of safety and efficacy for the treatment of indolent follicular non-Hodgkin’s lymphoma and mantle cell lymphoma. It is also developing an automated cell culture instrument. The company also sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies.

INVO Bioscience (OTC:IVOB) next catalysts to come

INVO Bioscience (OTC:IVOB) next catalysts to come

Next coming catalyst event for INVO Bioscience might come from Asia, with the expected Class II medical device classification for the INVOcell in China.

In August 10th, INVO Bioscience along with his distribution partner The Progressive Group, one of the larger med device and equipment distributors in this area, have started the registration process with Chinese FDA authorities.

Pullback Opportunity, exclusive interview with Hana Biosciences (OTC:HNAB)

Pullback Opportunity, exclusive interview with Hana Biosciences (OTC:HNAB)

“During the third quarter of 2010, our focus was on preparation of the 5 modules that make up the NDA submission for Marqibo(R)” stated Steven R. Deitcher, M.D., President and Chief Executive Officer of Hana Biosciences. “An analysis of data from the Menadione Topical Lotion Phase 1 program showed that it was generally safe and well tolerated. In addition, the dose limiting toxicity and apparent maximum tolerated lotion strength were identified. Our strategy is to seek a partner to enhance and accelerate the continued development of Menadione Topical Lotion.

INVO Bioscience (OTC:IVOB) released Amazing Clinical Study result for INVOcell

INVO Bioscience (OTC:IVOB) released Amazing Clinical Study result for INVOcell

The presentation revealed that CECOLFES produced clinical pregnancy rates of 43% per INVOcell cycle and a 48% clinical pregnancy rate when an embryo has been transferred in the cycle.

Understanding Warburg Pincus strategy: (OTC:HNAB), (NASDAQ:ISPH), (NASDAQ:ALTH), (NASDAQ:ZGEN), (NASDAQ:EURX), (NASDAQ:ITMN), (NYSE:WX)

Understanding Warburg Pincus strategy: (OTC:HNAB), (NASDAQ:ISPH), (NASDAQ:ALTH), (NASDAQ:ZGEN), (NASDAQ:EURX), (NASDAQ:ITMN), (NYSE:WX)

That might be a good time to look again at Hana Biosciences, as they have many catalysts and news to release before the end of 2010 that should drive shareholder value:

- Rolling NDA filling for Marqibo in Adult ALL (that means a PDUFA date and the classic run-up period)

- Top-line Menadione Topical Lotion proof-of-concept data

- Initiate Phase 2 Menadione Topical Lotion trial

- Phase 2 Study of Marqibo in Patients With Metastatic Uveal Melanoma with an estimated primary completion date of December 2010 (Final data collection date for primary outcome measure)

2011 might also be a very good year for Hana Biosciences, with the potential approval of Marqibo in Adult ALL and the start of Phase III studies for other indication with Marqibo ($5B market).

Delcath Systems (NASDAQ:DCTH) a breakthrough in the cancer treatment!

Delcath Systems (NASDAQ:DCTH) a breakthrough in the cancer treatment!

We believe the recent decline in the value of DCTH’s shares is an overreaction, certainly due to the stock offering and the little delay to submit the rolling NDA. The fundamental outlook for Delcath company remains strong. They have excellent clinical data, significant market opportunity and a strong balance sheet with enough cash for at least the next 12 months. In addition, Delcath continues to pursue negotiations with potential partners for international marketing rights for the Delcath PHP system.

INVO Bioscience, Inc. (OTC: IVOB), one more step in North America!

INVO Bioscience, Inc. (OTC: IVOB), one more step in North America!

The actual market cap of $2M is ridiculous considering that INVO Bioscience is becoming a strong and recognized company in the infertility field. With a unique device product already CE mark and an international distribution network in place, it would worth already at the very least 10 times the actual market cap! The Zack’s analyst has an outperform recommendation with a target price of $0.25.
We believe that major news are going to be released, we are awaiting for the clinical trial result in Columbia and have been told that it might be surprising and big, also a positive answer from the Federal R&D Tax Credit would be a very big news for the company and investors. The work already accomplished by the company is amazing and while it is taking more time than anticipated to increase revenue and resulting income, 2011 should improve dramatically for INVO Bioscience. With an estimated 150 million infertile couples worldwide, at the current market value of only $2M, we believe that this is dramatically underappreciated by Wall Street, recent developments and coming news should easily push up the price above the $0.20 range again.

Alexza Pharmaceuticals (NASDAQ:ALXA) on the way to agitate the market

Alexza Pharmaceuticals (NASDAQ:ALXA) on the way to agitate the market

Alexza’s lead candidate, AZ-004 is actually under FDA review with an action date schedule for October 11th 2010. We believe that their Staccato platform has the right combination of key attributes for the treatment of acute agitation that makes the product a $500M Market opportunity.

Back to Top

Social Media Profiles

ADVERTISEMENT

BUSINESS NETWORKS

The New York Times logo CNN logo ABC logo CNBC logo